MRS1845 is a selective store-operated calcium (SOC) channel inhibitor with an IC50 of 1.7 μM; it acts as an ORAI1 inhibitor. It effectively disrupts store-operated Ca2+ entry (SOCE) induced by β-glycerophosphate and significantly reduces SOCE, virtually abolishing the PlGF-induced enhancement of SOCE.